The finger-up-the-bottom examination for prostate cancer has been drawn into question. An international panel of experts recently suggested that so-called digital rectal examination for "active surveillance" should be replaced ...
Mar 7, 2023
0
6
The performance characteristics of prostate-specific membrane antigen positron emission tomography improves with increasing prostate-specific antigen (PSA) level. This, coupled with insurance approval concerns if applied ...
Mar 6, 2023
0
2
For patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according to a study presented at the American ...
Feb 17, 2023
0
3
Predicting the course of prostate cancer is challenging because only a fraction of prostate cancer patients experience recurrence after radical prostatectomy or radiation therapy. Yet, prostate cancer remains one of the most ...
Feb 14, 2023
0
24
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate ...
Feb 10, 2023
0
3
Researchers at the University of East Anglia have helped develop a new blood test to detect prostate cancer with greater accuracy than current methods.
Feb 8, 2023
0
7
Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology.
Jan 11, 2023
0
5
In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening ...
Oct 24, 2022
0
2
Psoriatic arthritis (PsA) screening is acceptable to patients with psoriasis whether they are diagnosed with PsA or not, according to a research letter published online Aug. 17 in the British Journal of Dermatology.
Sep 21, 2022
0
2
Prostate-specific antigen (PSA) screening is associated with decreased risk of prostate cancer-specific mortality (PCSM) among both Black and White men, according to a study published online Aug. 4 in JAMA Oncology.
Aug 10, 2022
0
2
